COMMITTED TO DISCOVERING BEST-IN-CLASS THERAPIES
TO CONQUER INFLAMMATORY and immunologic DISEASES

RAPT Therapeutics Announces Biomarker Data from Phase 1b Trial of RPT193 Consistent with Disease Modification in Atopic Dermatitis

March 28, 2022



« back to news page